Activating mutations in KRAS are common in colorectal cancer[47] but have also been reported in 5–16% of gastric and esophageal adenocarcinomas[27, 48, 49], causing unregulated signalling along its pathway, independently of EGFR status. The gene discussed is KRAS; the disease is esophageal adenocarcinoma.